Cranberry

Bladder Cancer

Hopital FochN/ADormant

D

30/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 15/ 100
Competitive Position: 73/ 100

Competitive context

98 Active assets in the Bladder Cancer cohort.

Asset / Sponsor	Phase	Rating
CIS-DIAMMINEDICHLOROPLATINUM II G1 Therapeutics, Inc.	Phase 3	BBB
Carboplatin G1 Therapeutics, Inc.	Phase 3	BB
Pembrolizumab Essen Biotech	Phase 3	BB
VINBLASTINE University of Southern California	Phase 3	BB
Epirubicin Merck Sharp & Dohme LLC	Phase 3	BB

View all 50 →

Same molecule, other indications

Cranberry is also rated in:

urinary tract infectionDormant

B

Indicative ·

62 / 100

urinary bladder disorderDormant

B

Indicative ·

62 / 100

multiple sclerosisDormant

CCC

Indicative ·

53 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.